DK3287142T3 - Fremgangsmåder til behandling af tilstande, som er forbundet med masp-2-afhængig komplementaktivering - Google Patents
Fremgangsmåder til behandling af tilstande, som er forbundet med masp-2-afhængig komplementaktivering Download PDFInfo
- Publication number
- DK3287142T3 DK3287142T3 DK17191208.2T DK17191208T DK3287142T3 DK 3287142 T3 DK3287142 T3 DK 3287142T3 DK 17191208 T DK17191208 T DK 17191208T DK 3287142 T3 DK3287142 T3 DK 3287142T3
- Authority
- DK
- Denmark
- Prior art keywords
- masp
- activation
- methods
- conditions associated
- treating conditions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161473698P | 2011-04-08 | 2011-04-08 | |
EP12767899.3A EP2694108B1 (en) | 2011-04-08 | 2012-04-06 | Methods for treating conditions associated with masp-2 dependent complement activation |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3287142T3 true DK3287142T3 (da) | 2021-11-01 |
Family
ID=46966283
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17191208.2T DK3287142T3 (da) | 2011-04-08 | 2012-04-06 | Fremgangsmåder til behandling af tilstande, som er forbundet med masp-2-afhængig komplementaktivering |
DK12767899.3T DK2694108T3 (da) | 2011-04-08 | 2012-04-06 | Fremgangsmåder til behandling af lidelser associeret med masp-2-afhængig komplementaktivering |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12767899.3T DK2694108T3 (da) | 2011-04-08 | 2012-04-06 | Fremgangsmåder til behandling af lidelser associeret med masp-2-afhængig komplementaktivering |
Country Status (18)
Country | Link |
---|---|
US (5) | US8951522B2 (da) |
EP (3) | EP3964233A1 (da) |
JP (4) | JP5937197B2 (da) |
KR (6) | KR102217658B1 (da) |
CN (3) | CN107638565B (da) |
AU (1) | AU2012239889B2 (da) |
BR (1) | BR112013025917A2 (da) |
CA (3) | CA3076975A1 (da) |
CL (1) | CL2013002874A1 (da) |
DK (2) | DK3287142T3 (da) |
ES (2) | ES2894342T3 (da) |
HK (1) | HK1250342A1 (da) |
IL (3) | IL228758B (da) |
MX (2) | MX355648B (da) |
NZ (5) | NZ617298A (da) |
PL (1) | PL3287142T3 (da) |
RU (2) | RU2662563C2 (da) |
WO (1) | WO2012139081A2 (da) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
MX355648B (es) | 2011-04-08 | 2018-04-26 | Univ Leicester | El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2. |
PE20150159A1 (es) | 2011-12-21 | 2015-02-08 | Novartis Ag | Composiciones y metodos para anticuerpos que actuan sobre el factor p |
US20130273053A1 (en) * | 2012-04-06 | 2013-10-17 | University Of Leicester | Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria |
RU2709351C2 (ru) * | 2012-06-18 | 2019-12-17 | Омерос Корпорейшн | Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения различных заболеваний и нарушений |
EP3722320A3 (en) * | 2012-10-25 | 2020-12-30 | Bioverativ USA Inc. | Anti-complement c1s antibodies and uses thereof |
JP6543572B2 (ja) | 2012-11-02 | 2019-07-10 | バイオベラティブ・ユーエスエイ・インコーポレイテッド | 抗補体C1s抗体とそれらの用途 |
WO2014144542A2 (en) * | 2013-03-15 | 2014-09-18 | Omeros Corporation | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same |
US20140363433A1 (en) | 2013-03-15 | 2014-12-11 | Omeros Corporation | Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same |
DK3057993T3 (en) | 2013-10-17 | 2020-11-16 | Omeros Corp | Method for Treating Conditions Associated with MASP-2 Dependent Complement |
WO2015070041A1 (en) * | 2013-11-08 | 2015-05-14 | Icahn School Of Medicine At Mount Sinai | Methods for monitoring kidney dysfunction |
PT3628680T (pt) | 2014-06-12 | 2021-10-07 | Ra Pharmaceuticals Inc | Modulação da atividade do complemento |
JP6640229B2 (ja) | 2015-01-28 | 2020-02-05 | ラ ファーマシューティカルズ インコーポレイテッドRa Pharmaceuticals,Inc. | 補体活性の変調剤 |
RS63956B1 (sr) | 2015-04-06 | 2023-02-28 | Bioverativ Usa Inc | Humanizovana anti-c1s antitela i metode njihove upotrebe |
WO2017083371A1 (en) * | 2015-11-09 | 2017-05-18 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
MX2018007352A (es) | 2015-12-16 | 2019-05-16 | Ra Pharmaceuticals Inc | Moduladores de la actividad del complemento. |
SI3394089T1 (sl) * | 2015-12-23 | 2021-12-31 | eleva GmbH | Polipeptidi za inhibiranje aktivacije komplementa |
SG11201805695SA (en) * | 2016-01-05 | 2018-07-30 | Univ Leicester | Methods for inhibiting fibrosis in a subject in need thereof |
CN115137816A (zh) * | 2016-03-31 | 2022-10-04 | 奥默罗斯公司 | 抑制有需要的受试者的血管发生的方法 |
JOP20170170B1 (ar) | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
JOP20190068A1 (ar) * | 2016-10-13 | 2019-04-01 | Omeros Corp | طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي |
MX2019006527A (es) | 2016-12-07 | 2019-08-01 | Ra Pharmaceuticals Inc | Moduladores de la actividad del complemento. |
WO2018124132A1 (ja) * | 2016-12-26 | 2018-07-05 | 日本ビーシージー製造株式会社 | 細菌細胞壁骨格成分を含有する水中油型エマルション製剤 |
US20200032270A1 (en) * | 2017-03-09 | 2020-01-30 | Kyowa Kirin Co., Ltd. | Nucleic acid capable of inhibiting expression of masp2 |
AU2018306411B2 (en) * | 2017-07-28 | 2022-03-31 | Lemonex Inc. | Pharmaceutical composition for preventing or treating liver cancer |
CN111683672A (zh) | 2017-12-04 | 2020-09-18 | Ra制药公司 | 补体活性调节剂 |
GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
KR20210016545A (ko) * | 2018-05-29 | 2021-02-16 | 오메로스 코포레이션 | Masp-2 억제제 및 사용 방법 |
RU2699040C1 (ru) * | 2018-07-23 | 2019-09-03 | Федеральное государственное бюджетное учреждение науки "Уральский научно-практический центр радиационной медицины Федерального медико-биологического агентства" (ФГБУН УНПЦ РМ ФМБА России) | Способ экстренной профилактики и лечения острой лучевой болезни (варианты) |
WO2020038377A1 (zh) | 2018-08-21 | 2020-02-27 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
EP3628735A1 (en) | 2018-09-25 | 2020-04-01 | Centre National De La Recherche Scientifique | Antisense rna targeting pmp22 for the treatment of charcot-marie-tooth 1a disease |
US11896674B2 (en) | 2018-09-30 | 2024-02-13 | Suzhou Ribo Life Science Co., Ltd. | SiRNA conjugate, preparation method therefor and use thereof |
BR112021008967A2 (pt) * | 2018-11-15 | 2021-08-17 | Ionis Pharmaceuticals, Inc. | moduladores da expressão de irf5 |
CN114729354A (zh) * | 2018-12-25 | 2022-07-08 | 中国医学科学院基础医学研究所 | 炎性相关疾病防治的小rna药物及其组合 |
JP2022524078A (ja) | 2019-03-08 | 2022-04-27 | ラ ファーマシューティカルズ インコーポレイテッド | 深部組織浸透性c5阻害剤としてのジルコプラン |
US20220162607A1 (en) * | 2019-03-14 | 2022-05-26 | Rena Therapeutics Inc. | Nucleic acid complex for modulating ihh expression |
US20230115176A1 (en) | 2019-03-29 | 2023-04-13 | Ra Pharmaceuticals, Inc. | Complement Modulators and Related Methods |
WO2020219822A1 (en) | 2019-04-24 | 2020-10-29 | Ra Pharmaceuticals, Inc. | Compositions and methods for modulating complement activity |
EP3974533A4 (en) * | 2019-05-22 | 2023-11-08 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD AND USE |
CN111024947A (zh) * | 2019-11-19 | 2020-04-17 | 江苏美克医学技术有限公司 | 白色念珠菌荧光免疫层析测定试剂盒及其制备方法 |
JP7227401B2 (ja) | 2019-11-27 | 2023-02-21 | 京セラ株式会社 | 通信制御方法及びユーザ装置 |
JP2023504543A (ja) | 2019-12-04 | 2023-02-03 | オメロス コーポレーション | Masp-2阻害剤および使用方法 |
CN115052604A (zh) | 2019-12-04 | 2022-09-13 | 奥默罗斯公司 | Masp-2抑制剂和使用方法 |
JP2023504542A (ja) | 2019-12-04 | 2023-02-03 | オメロス コーポレーション | Masp-2阻害剤および使用方法 |
AU2020395306A1 (en) | 2019-12-04 | 2022-06-30 | Omeros Corporation | MASP-2 inhibitors and methods of use |
EP4107165A1 (en) * | 2020-02-19 | 2022-12-28 | Alnylam Pharmaceuticals, Inc. | Mannan binding lectin serine peptidase 2 (masp2) irna compositions and methods of use thereof |
KR102314642B1 (ko) * | 2020-04-17 | 2021-10-20 | 재단법인 아산사회복지재단 | 파브리 병 진단용 바이오 마커 및 이의 용도 |
CN113674860A (zh) * | 2020-05-15 | 2021-11-19 | 北京大学人民医院 | 一种难治性iTTP风险预测装置、***及其应用 |
EP4331603A1 (en) * | 2021-04-25 | 2024-03-06 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-masp2 antibody, antigen-binding fragment thereof and medical use thereof |
WO2024026258A2 (en) * | 2022-07-25 | 2024-02-01 | Amgen Inc. | Rnai constructs and methods for inhibiting fam13a expression |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4394370A (en) | 1981-09-21 | 1983-07-19 | Jefferies Steven R | Bone graft material for osseous defects and method of making same |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4526909A (en) | 1984-01-09 | 1985-07-02 | Regents Of The University Of California | Polymethylmethacrylate delivery system for bone morphogenetic protein |
US4563489A (en) | 1984-02-10 | 1986-01-07 | University Of California | Biodegradable organic polymer delivery system for bone morphogenetic protein |
JPH0662679B2 (ja) | 1985-06-21 | 1994-08-17 | 新田ゼラチン株式会社 | 組織親和性コラ−ゲンとその製法 |
US5453566A (en) | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
RO114469B1 (ro) | 1987-12-15 | 1999-04-30 | Gene Shears Pty Ltd | Compus oligoribonucleotidic, procedeu de preparare si metoda de inactivare |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8822492D0 (en) | 1988-09-24 | 1988-10-26 | Considine J | Apparatus for removing tumours from hollow organs of body |
US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
SG46445A1 (en) | 1990-01-26 | 1998-02-20 | Immunomedics Inc | Vaccines against cancer and infectious diseases |
JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
US5856121A (en) | 1994-02-24 | 1999-01-05 | Case Western Reserve University | Growth arrest homebox gene |
JPH07238100A (ja) | 1994-02-25 | 1995-09-12 | Sumitomo Electric Ind Ltd | ヒトのmaspに対するモノクローナル抗体 |
US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
AU4467396A (en) | 1994-12-12 | 1996-07-10 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain, inflammation and spasm |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
US5739119A (en) | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
US7083786B2 (en) | 1997-04-03 | 2006-08-01 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
US6297024B1 (en) | 1998-10-15 | 2001-10-02 | Cell Activation, Inc. | Methods for assessing complement activation |
CA2347734A1 (en) | 1998-12-15 | 2000-06-22 | Brigham And Women's Hospital, Inc. | Methods and products for regulating lectin complement pathway associated complement activation |
US7273925B1 (en) | 1998-12-15 | 2007-09-25 | Brigham And Women's Hospital, Inc. | Methods and products for regulating lectin complement pathway associated complement activation |
US6235494B1 (en) | 1999-02-08 | 2001-05-22 | The Scripps Research Institute | Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates |
ES2308985T3 (es) | 1999-07-21 | 2008-12-16 | Omeros Corporation | Disoluciones y procedimientos para la inhibicion del dolor, inflamacion y degradacion del cartilago. |
US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
AU785149B2 (en) | 1999-12-02 | 2006-10-05 | Jens Christian Jensenius | MASP-3, a complement-fixing enzyme, and uses for it |
US6649592B1 (en) | 2000-01-14 | 2003-11-18 | Science & Technology Corporation @ Unm | Peptide inhibitors of LFA-1/ICAM-1 interaction |
SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
CA2415751C (en) | 2000-07-13 | 2015-06-16 | Steffen Thiel | Masp-2, a complement-fixing enzyme, and uses for it |
JP2004536138A (ja) | 2001-07-26 | 2004-12-02 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 認識機能を改善する方法 |
MXPA04007124A (es) | 2002-02-01 | 2004-10-29 | Omeros Corp | Composiciones y metodos para la inhibicion sistemica de la degradacion del cartilago. |
US20050221382A1 (en) | 2002-03-18 | 2005-10-06 | Rother Russell P | Stratification of patient populations having or suspected of having rheumatoid arthritis |
ES2601143T3 (es) | 2002-07-19 | 2017-02-14 | Omeros Corporation | Copolímeros tribloque biodegradables, métodos de síntesis de los mismos, e hidrogeles y biomateriales preparados a partir de los mismos |
CA2866848C (en) | 2002-07-30 | 2017-01-03 | Omeros Corporation | Ophthalmologic irrigation solutions and method |
ITRM20020511A1 (it) * | 2002-10-09 | 2004-04-10 | Santa Anna Acuto | Uso dell'insulator sns di riccio di mare per la terapia genica di malattie delle cellule eritroidi. |
US20060275764A1 (en) | 2002-12-03 | 2006-12-07 | Aarhus Universitet | Method for determining predisposition to manifestation of immune system related diseases |
AU2004216176B2 (en) | 2003-02-21 | 2008-04-03 | Genentech, Inc. | Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
CN1791614B (zh) * | 2003-03-17 | 2011-01-12 | 财团法人化学及血清疗法研究所 | 含抗von Willebrand因子特异性切割酶的抗体识别的结构域的构建体 |
HUE024996T2 (en) | 2003-05-12 | 2016-01-28 | Helion Biotech Aps | Anti-MASP-2 antibodies |
US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
PL1753456T3 (pl) * | 2004-06-10 | 2017-01-31 | Omeros Corporation | Sposoby leczenia stanów związanych z aktywacją dopełniacza zależną od masp-2 |
GB0412966D0 (en) | 2004-06-10 | 2004-07-14 | Univ Leicester | Genetically modified non-human mammals and cells |
US20060018896A1 (en) | 2004-06-10 | 2006-01-26 | University Of Leicester | Methods for treating conditions associated with lectin-dependent complement activation |
US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
PL1902141T3 (pl) * | 2005-06-17 | 2012-12-31 | Baxalta Inc | Kompozycje o działaniu trombolitycznym zawierające ADAMTS13 |
DE602007010246D1 (de) | 2006-01-27 | 2010-12-16 | Rappaport Family Inst For Res | Verfahren zur blutgerinnungsbestimmung |
PL2596807T3 (pl) | 2006-03-08 | 2016-06-30 | Archemix Llc | Aptamery wiążące dopełniacza i środki anty-C5 użyteczne w leczeniu zaburzeń ocznych |
EP2894165B1 (en) | 2008-11-10 | 2023-01-04 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
CN102597005A (zh) * | 2009-06-23 | 2012-07-18 | 阿雷克森制药公司 | 与补体蛋白质结合的双特异性抗体 |
EP2454281B1 (en) | 2009-07-17 | 2018-11-14 | Omeros Corporation | Masp isoforms as inhibitors of complement activation |
BR112012008970A2 (pt) | 2009-10-16 | 2019-12-10 | Omeros Corp | uso de uma composição, e, composição |
KR20120130748A (ko) * | 2009-11-05 | 2012-12-03 | 알렉시온 캠브리지 코포레이션 | 발작성 야간 혈색소뇨증, 용혈성 빈혈, 및 혈관내 및 혈관외 용혈을 수반한 질환 상태의 치료 |
AU2011223866B2 (en) | 2010-03-01 | 2015-05-21 | Alexion Pharmaceuticals Inc. | Methods and compositions for treating Degos' disease |
US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US20150166676A1 (en) | 2011-04-08 | 2015-06-18 | Omeros Corporation | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
MX355648B (es) | 2011-04-08 | 2018-04-26 | Univ Leicester | El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2. |
HUE049154T2 (hu) | 2011-05-04 | 2020-09-28 | Omeros Corp | Készítmények a MASP-2-függõ komplement-aktiválás gátlására |
RU2709351C2 (ru) | 2012-06-18 | 2019-12-17 | Омерос Корпорейшн | Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения различных заболеваний и нарушений |
DK3057993T3 (en) | 2013-10-17 | 2020-11-16 | Omeros Corp | Method for Treating Conditions Associated with MASP-2 Dependent Complement |
WO2017083371A1 (en) | 2015-11-09 | 2017-05-18 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
WO2018070521A1 (ja) * | 2016-10-14 | 2018-04-19 | 公立大学法人福島県立医科大学 | 補体の活性化経路を阻害する融合ポリペプチド |
-
2012
- 2012-04-06 MX MX2016006039A patent/MX355648B/es unknown
- 2012-04-06 CA CA3076975A patent/CA3076975A1/en active Pending
- 2012-04-06 ES ES17191208T patent/ES2894342T3/es active Active
- 2012-04-06 DK DK17191208.2T patent/DK3287142T3/da active
- 2012-04-06 CA CA2977009A patent/CA2977009C/en active Active
- 2012-04-06 EP EP21188935.7A patent/EP3964233A1/en active Pending
- 2012-04-06 EP EP17191208.2A patent/EP3287142B1/en active Active
- 2012-04-06 JP JP2014504058A patent/JP5937197B2/ja active Active
- 2012-04-06 US US13/441,827 patent/US8951522B2/en active Active
- 2012-04-06 NZ NZ617298A patent/NZ617298A/en unknown
- 2012-04-06 KR KR1020197037437A patent/KR102217658B1/ko active IP Right Grant
- 2012-04-06 BR BR112013025917A patent/BR112013025917A2/pt not_active Application Discontinuation
- 2012-04-06 NZ NZ746139A patent/NZ746139A/en unknown
- 2012-04-06 NZ NZ731596A patent/NZ731596A/en unknown
- 2012-04-06 KR KR1020217004368A patent/KR20210021101A/ko not_active Application Discontinuation
- 2012-04-06 RU RU2013149792A patent/RU2662563C2/ru active
- 2012-04-06 AU AU2012239889A patent/AU2012239889B2/en active Active
- 2012-04-06 WO PCT/US2012/032650 patent/WO2012139081A2/en active Application Filing
- 2012-04-06 EP EP12767899.3A patent/EP2694108B1/en active Active
- 2012-04-06 RU RU2018125514A patent/RU2743409C2/ru active
- 2012-04-06 CA CA2832187A patent/CA2832187C/en active Active
- 2012-04-06 MX MX2013011721A patent/MX339002B/es active IP Right Grant
- 2012-04-06 KR KR1020227010108A patent/KR20220044616A/ko not_active Application Discontinuation
- 2012-04-06 CN CN201710646474.7A patent/CN107638565B/zh active Active
- 2012-04-06 NZ NZ717517A patent/NZ717517A/en unknown
- 2012-04-06 CN CN201910000825.6A patent/CN110075294A/zh active Pending
- 2012-04-06 ES ES12767899T patent/ES2683307T3/es active Active
- 2012-04-06 KR KR1020137029501A patent/KR101720562B1/ko active IP Right Grant
- 2012-04-06 KR KR1020177007747A patent/KR101870915B1/ko active IP Right Grant
- 2012-04-06 PL PL17191208T patent/PL3287142T3/pl unknown
- 2012-04-06 CN CN201280028263.2A patent/CN103781492A/zh active Pending
- 2012-04-06 KR KR1020187017317A patent/KR20180072851A/ko active Application Filing
- 2012-04-06 NZ NZ709997A patent/NZ709997A/en unknown
- 2012-04-06 DK DK12767899.3T patent/DK2694108T3/da active
-
2013
- 2013-10-06 IL IL228758A patent/IL228758B/en active IP Right Grant
- 2013-10-07 CL CL2013002874A patent/CL2013002874A1/es unknown
-
2014
- 2014-12-23 US US14/581,191 patent/US20150239985A1/en not_active Abandoned
-
2016
- 2016-05-11 JP JP2016095034A patent/JP6239030B2/ja active Active
- 2016-12-07 US US15/371,726 patent/US10202465B2/en active Active
-
2017
- 2017-10-31 JP JP2017209894A patent/JP6584476B2/ja active Active
-
2018
- 2018-07-30 HK HK18109793.0A patent/HK1250342A1/zh unknown
- 2018-12-17 US US16/222,188 patent/US20190292272A1/en not_active Abandoned
-
2019
- 2019-01-09 IL IL264172A patent/IL264172B/en unknown
- 2019-09-03 JP JP2019160040A patent/JP6893539B2/ja active Active
-
2020
- 2020-04-23 IL IL274206A patent/IL274206A/en unknown
-
2021
- 2021-09-09 US US17/470,386 patent/US20220089781A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3287142T3 (da) | Fremgangsmåder til behandling af tilstande, som er forbundet med masp-2-afhængig komplementaktivering | |
DK2683384T3 (da) | Fremgangsmåder til behandling af cancer under anvendelse af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion | |
DK2709613T4 (da) | Fremgangsmåder til behandling af hcv | |
DK2714735T3 (da) | Antistoffer, der er specifikke for TGF-beta | |
BR112013019984A2 (pt) | método para controlar um aparelho eletrônico, e aparelho eletrônico. | |
BR112014032116A2 (pt) | método. | |
DK2970383T3 (da) | Fremgangsmåde til behandling af fibrose | |
DK3366293T3 (da) | Dihydronaphthyridiner og relaterede forbindelser, der er nyttige som kinashæmmere til behandling af proliferative sygdomme | |
CO6890100A2 (es) | Tratamientos de combinación para hepatitis c | |
BR302012000171S1 (pt) | Configuração aplicada em copo para bebida. | |
DK2741763T3 (da) | Sammensætning til kontrolleret ovariestimulering. | |
BR112013022306A2 (pt) | método, e, composição | |
BR112014012759A8 (pt) | composto, composição e método para tratamento | |
BR112013019224A2 (pt) | composição, e metodo | |
DK2986325T3 (da) | Fremgangsmåder til behandling af forstyrrelser i urinstofcyklus | |
BR112014014169A2 (pt) | válvula automática | |
DK3404041T3 (da) | Fremgangsmåde til behandling af osteoporose | |
FR2978994B1 (fr) | . | |
DK2522421T3 (da) | Fremgangsmåde til opnåelse af mikrokapsler | |
DK3372580T3 (da) | Fremgangsmåde til fremstilling af 1-h-pyrrolidin-2,4-dion-derivater | |
DE102011111940A8 (de) | Begehbares flachlaufendes Tor | |
FR2972936B1 (fr) | Poignee bloqueuse. | |
BR112014030576A2 (pt) | composto, e, método para controlar micro-organismos. | |
DK2688414T3 (da) | Fremgangsmåde til fremstilling af brød | |
DE102011000200A8 (de) | Automatik-Gripzange |